Biopsie tissulaire et biopsie liquide, une complémentarité devenue incontournable en oncologie thoracique

Abstract

AbstractThe concept of liquid biopsy (LB) led to different opportunities in the domain of thoracic oncology, some of them have been transferred in the routine clinical practice associated with the care of advanced non-squamous non-small cell lung cancer (aNS-NSCL). The LB can be realized at tumor progression in patients treated with EGFR or ALK tyrosine kinase inhibitors. A tissue biopsy targeting a site of tumor progression has to be done, notably if the LB did not identify a resistance mechanism associated with a genomic alteration. The practice of a LB in treatment naïve aNE-NSCL is recommended if tissular or cytological material is not available and/or if extracted nucleic acids are in low quantity and/or are degraded. The systematic practice of both liquid and tissue biopsies before treatment or at tumor progression is rarely performed routinely nowadays. This approach is currently under evaluation in certain institutions in order to evaluate its added value for the care of aNE-NSCLC. The point is made here on the different complementarities which can be made by the liquid and the tissue biopsy in the context of medical care of NS-NSCLC.